End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
05-29 | UBS Adjusts DuPont de Nemours Price Target to $98 From $93, Maintains Buy Rating | MT |
05-28 | DuPont's Breakup Plan Holds Logic Amid Disadvantages, BofA Says | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Sales forecast by analysts have been recently revised upwards.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.32 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.24 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 34.35B | - | ||
-1.05% | 74.34B | B | ||
-0.76% | 46.86B | A- | ||
+9.37% | 18.1B | B | ||
+12.81% | 11.92B | A- | ||
-3.01% | 10.43B | - | ||
-20.72% | 10.33B | B | ||
-1.35% | 9.04B | A- | ||
-11.01% | 7.84B | C- | ||
-3.85% | 7.52B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DD Stock
- DOWCP Stock
- Ratings DuPont de Nemours